Related Experiment Video

Updated: Dec 24, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.0K

Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance

Andriy Marusyk1, Michalina Janiszewska2, Kornelia Polyak3

  • 1Department of Cancer Physiology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.

Cancer Cell
|April 15, 2020
PubMed

Insights

Tumor cells develop resistance to targeted therapies due to pre-existing diversity within tumors. Understanding and targeting this intratumor heterogeneity is key to improving cancer treatment outcomes.

Area of Science:

  • Oncology
  • Cancer Biology
  • Molecular Therapeutics

Background:

  • Targeted therapies offer promising cancer treatments by inhibiting specific oncogenic pathways.
  • Despite initial success, acquired resistance and tumor relapse remain significant challenges in advanced cancers.
  • Immune-based therapies also face obstacles due to acquired resistance, limiting complete cures.

Purpose of the Study:

  • To review the sources of intratumor heterogeneity (ITH) in cancer.
  • To discuss methods for capturing and utilizing ITH in clinical decision-making.
  • To outline strategies for targeting ITH to overcome therapeutic resistance.

Main Methods:

  • Literature review on tumorigenesis, targeted therapy, immunotherapy, and cancer resistance mechanisms.
  • Analysis of the role of intratumor heterogeneity in treatment failure.
  • Exploration of clinical strategies for managing ITH.

Main Results:

  • Acquired resistance stems from pre-existing ITH and therapy-induced diversification.
  • ITH allows a subset of tumor cells to survive treatment and develop resistance.
  • Current therapeutic approaches often fail to fully address the complexity of ITH.

Conclusions:

  • Intratumor heterogeneity is a fundamental driver of acquired resistance to cancer therapies.
  • Accounting for ITH in clinical decision-making is crucial for optimizing treatment.
  • Developing strategies that directly target ITH holds potential for improving therapeutic efficacy and achieving durable responses.
Keywords:
cancerheterogeneitytherapeutic resistance

More Related Videos

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.0K
Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation10:24

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation

Published on: September 19, 2019

6.6K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.8K